The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors

Abstract. In order to elucidate the value of positron emission tomography (PET)/computed tomography (CT) in the clinical diagnosis and treatment of osseous and soft tissue malignancies, two authors independently searched the PubMed, Medline, Elsevier, Embase and Cochrane Library databases for literature published between January 2003 and February 2016, using the key words 'PET/CT', 'positron emission tomography/computed tomography', 'osseous sarcoma', 'bone tumor', 'soft tissue sarcoma' and 'neoadjuvant', to identify prospective and retrospective studies on the applicability of PET/CT on the clinical diagnosis of bone and soft tissue lesions, and evaluation of their response to neoadjuvant therapies. Data were independently extracted by the two authors and any disagreements were resolved by a third author when necessary. Extracted data were analyzed by Meta-Disc 1.6 software. As a result, 16 trials with a total of 883 patients and 2,214 lesions were included in the present study. The overall diagnostic accuracy of PET/CT exhibited a sensitivity and specificity of 0.90 (0.86-0.92) and 0.89 (0.85-0.92), respectively, and the effect of neoadjuvant therapy was assessed with a sensitivity and specificity of 0.79 (0.30-0.93) and 0.79 (0.69-0.89), respectively. Thus, it may be concluded from the present study that PET/CT is a reliable imaging method to be applied in the diagnosis and treatment of osseous and soft tissue malignancies.

show abstract

“…Of the 1,310 articles screened, 16 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) were selected for the final analysis (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis

Muheremu

Amudong

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, the use of PET imaging in the differential diagnosis between benign and malignant bone tumours has been debated because high accumulation of fludeoxyglucose (FDG) can be observed in some benign bone lesions, especially histiocytic or giant cell containing lesions [6]. Previous studies have reported that the maximal standardised uptake value (SUV max ) of haemangioma was less than 2.5 on fluorine-18-FDG ( 18 F-FDG) PET/CT [6][7][8][9]. To our knowledge, these atypical 18 F-FDG PET/CT findings of intra-osseous haemangioma have not been previously reported.…”

mentioning

confidence: 99%

PET/CT and MRI of intra-osseous haemangioma of the tibia

Yoo²,

Kim³

et al. 2012

BJR

View full text Add to dashboard Cite

ABSTRACT. Intra-osseous haemangioma is a rare, benign neoplasm that usually involves the vertebrae and craniofacial bones. Furthermore, its occurrence in the long bones is extremely rare. We report the findings of fluorine-18-fludeoxyglucose ( F-FDG PET/CT showed a well-marginated osteolytic lesion with abnormal FDG uptake. The mass demonstrated low signal intensity on T 1 weighted MRI. On T 2 weighted images, the lesion appeared as a cluster of high signal intensity lobules and showed strong enhancement on contrast-enhanced T 1 weighted images. Surgical curettage was performed and histopathological examination of the excised tissue confirmed a cavernous haemangioma.

show abstract

“…Positron emission tomography (PET) using 18 F FDG is being used along with computed tomography (CT) and magnetic resonance imaging (MRI) in differentiation of benign and malignant intraosseous lesions. Nuclear medicine physicians should be aware of a high accumulation of FDG in some benign bone tumors and tumor like lesions, specially histocytic and Giant cell containing lesions.…”

Section: Resultsmentioning

confidence: 99%

“…Nuclear medicine physicians should be aware of a high accumulation of FDG in some benign bone tumors and tumor like lesions, specially histocytic and Giant cell containing lesions. Dual-time point 18 F FDG PET may provide more help in this differentiation and is specially recommended for the unclear bone lesions.…”

Section: Resultsmentioning

confidence: 99%